Psoriasis is a chronic systemic autoimmune disease associated with an elevated risk of developing cardiovascular disease. In patients with psoriasis, arterial hypertension treatment requires careful selection of antihypertensive drugs, as some drugs may worsen the skin manifestations of psoriasis. In this review, we summarize the available evidence regarding the risks and benefits of each group of antihypertensive drugs. We also suggest a scheme for optimizing antihypertensive treatment in patients with psoriasis, with emphasis on achieving effective control of blood pressure and cardiovascular disease, while minimizing the worsening of cutaneous manifestations. Angiotensin receptor blockers appear to be the most appropriate treatment for hypertensive patients with psoriasis, with the potential addition of calcium channel blockers if blood pressure is not adequately controlled. Alternatives are angiotensin-converting enzyme inhibitors and/or mineralocorticoid receptor antagonists. Diuretics and beta blockers are associated with greater risk of worsening of psoriatic lesions.

Centre for Research on Internal and Cardiovascular Diseases Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Internal Medicine and Cardiology University Hospital Ostrava

Zobrazit více v PubMed

Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64: (Suppl 2): ii30–ii36. PubMed PMC

Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021; 6:402. PubMed PMC

Song G, Kim JY, Yoon HY, Yee J, Gwak HS. A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence. Sci Rep 2021; 11:10037. PubMed PMC

Ganeva M, Tsokeva Z, Gancheva T, Hristakieva E, Tsoneva V, Manolova I. Serum concentrations of 25-OH vitamin D and the pro-inflammatory interleukins IL-17, IL-23, and IL-18 in patients with plaque psoriasis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2024; 168:124–131. PubMed

Furtunescu AR, Georgescu SR, Tampa M, Matei C. Inhibition of the JAK-STAT pathway in the treatment of psoriasis: a review of the literature. Int J Mol Sci 2024; 25:4681. PubMed PMC

Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol 2022; 13:880201. PubMed PMC

Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. . EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34:2461–2498. PubMed

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. . FIDELIO-DKD Investigators. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219–2229. PubMed

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. ESC Scientific Document Group, 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J 2024;45:3912–4018.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–324. oi:10.1161/HYP.0000000000000066. PubMed

Jeemon P, Séverin T, Amodeo C, Balabanova D, Campbell NRC, Gaita D, et al. . World Heart Federation roadmap for hypertension – a 2021 update. Glob Heart 2021; 16:63. PubMed PMC

Wu S, Han J, Li WQ, Qureshi AA, Hypertension. antihypertensive medication use, and risk of psoriasis. JAMA Dermatol 2014; 150:957–963. PubMed PMC

Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 2010; 3:32–38. PubMed PMC

Herman LL, Padala SA, Ahmed I, et al. Angiotensin-converting enzyme inhibitors (ACEI) [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK431051/. PubMed

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370:263–271. PubMed

Sandmann S, Unger T. Implications physiopathologiques et cliniques des récepteurs AT(1)/AT(2) de l’angiotensine II dans l’insuffisance cardiaque, coronaire et rénale [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure]. Drugs. 2002;62(Spec No 1):43–52. In French. PMID: 12036388. PubMed

Oláh A, Szöllősi AG, Bíró T. The channel physiology of the skin. Rev Physiol Biochem Pharmacol 2012; 163:65–131. PubMed

Wang M, Sun Y, Li L, Wu P, Dkw O, Shi H. Calcium channels: noteworthy regulators and therapeutic targets in dermatological diseases. Front Pharmacol 2021; 12:702264. PubMed PMC

Lehen’kyi V, Beck B, Polakowska R, Charveron M, Bordat P, Skryma R, et al. . TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes. J Biol Chem 2007; 282:22582–22591. PubMed

Azzouz B, Abou Taam M, Morel A, Trenque T. Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reaction. Expert Opin Drug Saf 2018; 17:853–857. PubMed

McKeever RG, Patel P, Hamilton RJ. Calcium channel blockers. [Updated 2024 Feb 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482473/. PubMed

Azzouz B, Laugier-Castellan D, Sanchez-Pena P, Rouault M, Kanagaratnam L, Morel A, et al. . Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature data. Therapie 2021; 76:5–11. PubMed

Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010; 8:793–802. PubMed PMC

Awad VM, Sakhamuru S, Kambampati S, Wasim S, Malik BH. Mechanisms of beta-blocker induced psoriasis, and psoriasis de novo at the cellular level. Cureus 2020; 12:e8964. PubMed PMC

Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. . Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 2015; 151:161–169. PubMed PMC

Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis and hypertension severity: results from a case-control study. PLoS One 2011; 6:e18227. PubMed PMC

Sevilla LM, Pérez P. Roles of the glucocorticoid and mineralocorticoid receptors in skin pathophysiology. Int J Mol Sci 2018; 19:1906. PubMed PMC

Václavík J, Sedlák R, Jarkovský J, Kociánová E, Táborský M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) 2014; 93:e162. PubMed PMC

Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, et al. . FIGARO-DKD Investigators. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial. Circulation 2022; 145:437–447. PubMed PMC

Nicolas D, Kerndt CC, Patel P, Reed M. Sacubitril-Valsartan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 29939681. PubMed